MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inefficient immune response is a major glitch during tumor growth and progression. Chaotic and leaky blood vessels created in the process of angiogenesis allow tumor cells to escape and extricate anti-cancer immunity. Proangiogenic characteristics of hypoxic tumor microenvironment maintained by low oxygen tension attract endothelial progenitor cells, drive expansion of cancer stem cells, and deviantly differentiate monocyte descendants. Such cellular milieu further boosts immune tolerance and eventually appoint immunity for cancer advantage. Blood vessel normalization strategies that equilibrate oxygen levels within tumor and fix abnormal vasculature bring exciting promises to future anticancer therapies especially when combined with conventional chemotherapy. Recently, a new group of microRNAs (miRs) engaged in angiogenesis, called angiomiRs and hypoxamiRs, emerged as new therapeutic targets in cancer. Some of those miRs were found to efficiently regulate cancer immunity and their dysregulation efficiently programs aberrant angiogenesis and cancer metastasis. The present review highlights new findings in the field of miRs proficiency to normalize aberrant angiogenesis and to restore anti-tumor immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626 · cited 2×
“For example, hematopoietic cells are characterized by the following miRs: miR-142, -144, -150, -155, and 223 (Landgraf et al. 2007).”
BackgroundSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · cited 2×
“Especially anti-VEGF monotherapies failed (Carmeliet and Jain 2011a; Cobleigh et al. 2003; Giantonio et al. 2007; Jain et al. 2006) since anti-VEGF/VEGFR treatments boost hypoxic state that further allow for selection of highly resistant and aggressive stem-like cancer cells with progressively lower response to conven…”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Requirement of bic/microRNA-155 for Normal Immune Function
Rodriguez, A., Vigorito, E., Clare, S., Warren, M. V., Couttet, P., Soond, D. R., van Dongen, S., Grocock, R. J., Das, P. P., Miska, E. A., et al. (2007) · Science · doi:10.1126/science.1139253 · Cited by 1,833 · cited 3×
“miR-155 plays a crucial role in development, maintenance, and function of immune system (Rodriguez et al. 2007).”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 1×
“It states that cautious use of anti-angiogenic therapy creates a ''normalization window'' that reverses aberrant angiogenesis, leads to normalized vascular phenotype, and reduces vessel permeability and hypoxia (Goel et al. 2011, 2012).”
BackgroundTili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., Fabbri, M., Alder, H., Liu, C. G., Calin, G. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5082 · Cited by 1,304 · cited 3×
“…of human NK cell activation Okada et al. (2010) Association in the response to TLR ligands, PAMPs and role in differentiation of Th1 vs. Th2 T cells Tili et al. (2007) Regulation of the release of inflammatory mediators during the innate immune response Lu et al. (2009) O'Connell et al. (2009)…”
BackgroundRegulation of progenitor cell proliferation and granulocyte function by microRNA-223
Johnnidis, J. B., Harris, M. H., Wheeler, R. T., Stehling-Sun, S., Lam, M. H., Kirak, O., Brummelkamp, T. R., Fleming, M. D., & Camargo, F. D. (2008) · Nature · doi:10.1038/nature06607 · Cited by 1,208
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 1×
“Current aims of anti-angiogenic therapy is to create a normalization window where blood vessels regain their typical structure with decreased permeability for better drug penetration (Jain 2005; Tong et al. 2004; Wildiers et al. 2003).”
BackgroundA MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055 · cited 1×
“…(Chan et al. 2011) miR-31 (Liu et al. 2010) miR-378 (Fang et al. 2012) miR-107 (Yamakuchi et al. 2010) miR-449a/b (Muth et al. 2010) miR-130 (Kulshreshtha et al. 2007; Saito et al. 2011) miR-138 (Song et al. 2011) miR-199a (Mizuno et al. 2012) miR-519c (Cha et al. 2010) The miRs classifed…”
Cited by
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis
Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581007 · Cited by 288
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00602-3 · Cited by 267
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Klimkiewicz, K., Weglarczyk, K., Collet, G., Paprocka, M., Guichard, A., Sarna, M., Jozkowicz, A., Dulak, J., Sarna, T., Grillon, C., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.006 · Cited by 70
“The angiogenesis-controlling MiRs, angiomiRs and hypoxamiRs, are induced by tumour hypoxia and often promote pathologic vasculature; thus they constitute therapeutic targets [22].”
BackgroundSelf-citation
Metadata
- Authors
- Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C.
- Venue
- Archivum Immunologiae et Therapiae Experimentalis
- Publisher
- Walter de Gruyter GmbH
- Published
- 2013-04-11
- Volume
- 61
- Issue
- 4
- Pages
- 285-299
- ISSN
- 0004-069X (ISSN-L)
- 1661-4917
- OpenAlex
- W2041884448
- Cited by
- 30
- References
- 43
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response. https://app.cochat.ai/papers/10.1007/s00005-013-0231-4
- The paper
- Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C. (2013). MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.1007/s00005-013-0231-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.